Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Eledon Pharmaceuticals, Inc. (ELDN : NSDQ)

• Company Description    Eledon Pharmaceuticals Inc. is a clinical stage biotechnology company. It develop treatments for an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Eledon Pharmaceuticals Inc., formerly known as Novus Therapeutics Inc., is based in IRVINE, Calif. Number of Employees: 31

• Price / Volume Information    Yesterday's Closing Price: $1.51 Daily Weekly Monthly 20 Day Moving Average: 842,892 shares Shares Outstanding: 59.93 (millions) Market Capitalization: $90.50 (millions) Beta: 0.89 52 Week High: $4.98 52 Week Low: $1.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.03% -4.87% 12 Week -49.33% -50.15% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 19800 MACARTHUR BOULEVARD SUITE 250 - IRVINE,CA 92612 USA ph: 949-238-8090 fax: - investors@eledon.com http://www.eledon.com

• General Corporate Information    Officers David-Alexandre C. Gros - Chief Executive Officer and Director Keith A. Katkin - Chairman Paul Little - Chief Financial Officer Jan Hillson - Director James Robinson - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 28617K101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/19/26 Share - Related Items Shares Outstanding: 59.93 Most Recent Split Date: 10.00 (0.06:1) Beta: 0.89 Market Capitalization: $90.50 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.81 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/19/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.56 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 34.38% vs. Previous Quarter: -61.54% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -154.16 06/30/25 - -92.51 ROA 12/31/25 - - 09/30/25 - -52.02 06/30/25 - -38.31 Current Ratio 12/31/25 - - 09/30/25 - 6.74 06/30/25 - 8.12 Quick Ratio 12/31/25 - - 09/30/25 - 6.74 06/30/25 - 8.12 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 0.59 06/30/25 - 0.84 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©